Genelux Corp. (GNLX) Price & Analysis

Compare

259 Followers

GNLX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.60 - $5.89

Previous CloseN/A

Volume23.79K

Average Volume (3M)140.61K

Market Cap

$128.01M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.70

Next Earnings

Aug 19, 2025

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding37,760,840

10 Day Avg. Volume169,637

30 Day Avg. Volume140,613

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$16.40

Price Target Upside391.02% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical TrialsOlvi-Vec has shown highly differentiating efficacy in ovarian cancer, demonstrating positive monotherapy activity and the potential to re-sensitize patients to platinum chemotherapy.

Financial StabilityThe company secured $10.5 million in equity financing, extending its financial runway into 2026, supporting further development efforts.

Safety ProfileThe positive safety profile of Olvi-Vec with mostly mild to moderate adverse events and no maximum tolerated dose reached is encouraging for future trials.

Bears Say

Financial PerformanceGenelux reported a net loss, but maintains sufficient cash and short-term investments to support operations into 2026.

Regulatory ChallengesReplimune's oncolytic virus received a CRL from the FDA, highlighting challenges in obtaining approval for similar treatments, although this is not seen as impacting Olvi-Vec.

Regulatory RecommendationsFDA recommended adding an interim overall survival analysis to the ovarian cancer trial, indicating confidence in the progression-free survival outcomes.

Genelux Corp. News

Genelux initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Genelux (GNLX) with a Buy rating and $10 price target Genelux is a...

10d ago

GNLX

Genelux appoints Eric Groen as general counsel, corporate secretary, CCO

Genelux Corporation (GNLX) announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and...

24d ago

GNLX

RANI

Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Genelux Corp.. The associated price target...

8d ago

GNLX

Genelux Corp: A Promising Investment in the Oncolytic Virus Space with Key Clinical Milestones Ahead

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Genelux Corp., retaining the price target of...

14d ago

GNLX

Genelux Corp.’s Promising Prospects: Buy Rating Backed by Strong Phase 3 Trial and Financial Position

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Genelux Corp. (GNLX – Research Report), retaining...

3M ago

GNLX

Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Genelux Corp. (GNLX – Research Report)....

3M ago

GNLX

Genelux reports Q1 EPS (21c), consensus (24c)

“The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead....

3M ago

GNLX

Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Genelux Corp. (GNLX – Research Report) and...

4M ago

GNLX

Genelux reports FY24 EPS (95c), consensus (88c)

“Our progress in the fourth quarter of 2024 and into 2025 marks a pivotal period for patients, our...

4M ago

GNLX

Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp.

Maxim Group analyst Jason McCarthy has maintained their bullish stance on GNLX stock, giving a Buy rating yesterday....

4M ago

GNLX

Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec

Genelux (GNLX) Corporation announced preliminary safety and anti-tumor activity data from the dose escalation Phase 1b portion of...

4M ago

GNLX

Genelux announces alignment with FDA of approval pathway for Olvi-Vec

Genelux (GNLX) Corporation announced that Genelux has concluded a productive Type D meeting with the U.S. Food and...

4M ago

GNLX

Genelux prices 3M shares at $3.50 in underwritten public offering

Genelux (GNLX) announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an...

4M ago

GNLX

One new option listing on February 19th

New option listings for February 19th include Genelux Corp (GNLX). Published first on TheFly – the ultimate source...

5M ago

GNLX

GNLX FAQ

What was Genelux Corp.’s price range in the past 12 months?

Genelux Corp. lowest stock price was $1.60 and its highest was $5.88 in the past 12 months.

What is Genelux Corp.’s market cap?

Genelux Corp.’s market cap is $128.01M.

When is Genelux Corp.’s upcoming earnings report date?

Genelux Corp.’s upcoming earnings report date is Aug 19, 2025 which is in 19 days.

How were Genelux Corp.’s earnings last quarter?

Genelux Corp. released its earnings results on May 06, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.242 by $0.032.

Is Genelux Corp. overvalued?

According to Wall Street analysts Genelux Corp.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Genelux Corp. pay dividends?

Genelux Corp. does not currently pay dividends.

What is Genelux Corp.’s EPS estimate?

Genelux Corp.’s EPS estimate is -0.22.

How many shares outstanding does Genelux Corp. have?

Genelux Corp. has 37,760,840 shares outstanding.

What happened to Genelux Corp.’s price movement after its last earnings report?

Genelux Corp. reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.242. Following the earnings report the stock price went down -0.429%.

Which hedge fund is a major shareholder of Genelux Corp.?

Among the largest hedge funds holding Genelux Corp.’s share is Highbridge Capital Management LLC. It holds Genelux Corp.’s shares valued at 0.

Genelux Corp. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-131.36%

Trailing 12-Months

Asset Growth

57.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Genelux Corp.

Genelux Corp. (GNLX) is a biotechnology company focused on the research, development, and commercialization of oncolytic viral therapies for the treatment of cancer. The company operates within the biopharmaceutical sector, leveraging its proprietary technology platform to design and engineer viruses that selectively target and destroy cancer cells while sparing healthy tissue. Genelux aims to provide innovative treatment options that improve patient outcomes in oncology.

Genelux Corp. (GNLX) Earnings & Revenues

GNLX Earnings Data >

GNLX Stock 12 Month Forecast

Average Price Target

$16.40

▲(391.02%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","8":"$8","16":"$16","24":"$24","32":"$32"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,8,16,24,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Oct<br/>2024","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,4.996923076923077,7.163846153846154,9.330769230769231,11.497692307692308,13.664615384615384,15.831538461538463,17.99846153846154,20.165384615384617,22.332307692307694,24.49923076923077,26.666153846153847,28.833076923076923,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,3.873846153846154,4.917692307692308,5.961538461538461,7.005384615384615,8.049230769230768,9.093076923076922,10.136923076923075,11.18076923076923,12.224615384615383,13.268461538461537,14.31230769230769,15.356153846153843,{"y":16.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.83,3.227692307692308,3.6253846153846156,4.023076923076923,4.420769230769231,4.818461538461539,5.216153846153846,5.613846153846154,6.0115384615384615,6.409230769230769,6.806923076923077,7.204615384615384,7.602307692307692,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.09,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.75,"date":1696118400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.81,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.24,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >